A detailed history of Nuveen Asset Management, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 4,986,417 shares of GILD stock, worth $417 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
4,986,417
Previous 8,570,570 41.82%
Holding current value
$417 Million
Previous $628 Million 45.5%
% of portfolio
0.1%
Previous 0.19%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$63.15 - $72.88 $226 Million - $261 Million
-3,584,153 Reduced 41.82%
4,986,417 $342 Million
Q1 2024

May 13, 2024

SELL
$71.58 - $87.29 $212 Million - $259 Million
-2,964,905 Reduced 25.7%
8,570,570 $628 Million
Q4 2023

Feb 14, 2024

BUY
$73.27 - $83.09 $8.89 Million - $10.1 Million
121,326 Added 1.06%
11,535,475 $934 Million
Q3 2023

Nov 14, 2023

BUY
$73.94 - $80.67 $119 Million - $130 Million
1,614,798 Added 16.48%
11,414,149 $855 Million
Q2 2023

Aug 14, 2023

BUY
$76.01 - $86.7 $40.3 Million - $46 Million
530,242 Added 5.72%
9,799,351 $755 Million
Q1 2023

May 15, 2023

BUY
$77.31 - $88.08 $47.5 Million - $54.1 Million
614,202 Added 7.1%
9,269,109 $769 Million
Q4 2022

Feb 14, 2023

BUY
$62.32 - $89.47 $41.3 Million - $59.4 Million
663,387 Added 8.3%
8,654,907 $743 Million
Q3 2022

Nov 14, 2022

BUY
$59.54 - $68.01 $66.9 Million - $76.4 Million
1,123,549 Added 16.36%
7,991,520 $493 Million
Q2 2022

Aug 15, 2022

SELL
$57.72 - $65.01 $44.3 Million - $49.8 Million
-766,659 Reduced 10.04%
6,867,971 $425 Million
Q1 2022

May 16, 2022

SELL
$57.92 - $72.58 $78.9 Million - $98.8 Million
-1,361,924 Reduced 15.14%
7,634,630 $455 Million
Q4 2021

Feb 14, 2022

SELL
$64.88 - $73.64 $18.1 Million - $20.5 Million
-278,343 Reduced 3.0%
8,996,554 $653 Million
Q3 2021

Nov 12, 2021

BUY
$67.69 - $73.03 $27.6 Million - $29.7 Million
407,151 Added 4.59%
9,274,897 $648 Million
Q2 2021

Aug 16, 2021

BUY
$63.47 - $69.35 $9.45 Million - $10.3 Million
148,891 Added 1.71%
8,867,746 $611 Million
Q1 2021

May 17, 2021

BUY
$60.0 - $68.46 $235 Million - $268 Million
3,918,666 Added 81.64%
8,718,855 $564 Million
Q4 2020

May 17, 2021

BUY
$56.65 - $64.55 $12.1 Million - $13.8 Million
213,662 Added 4.66%
4,800,189 $280 Million
Q4 2020

Feb 16, 2021

SELL
$56.65 - $64.55 $8.97 Million - $10.2 Million
-158,356 Reduced 3.34%
4,586,527 $267 Million
Q3 2020

Nov 16, 2020

SELL
$62.1 - $78.08 $101 Million - $127 Million
-1,626,848 Reduced 25.53%
4,744,883 $300 Million
Q2 2020

Aug 14, 2020

SELL
$72.34 - $84.0 $439 Million - $510 Million
-6,067,783 Reduced 48.78%
6,371,731 $490 Million
Q1 2020

May 14, 2020

BUY
$62.63 - $80.22 $259 Million - $332 Million
4,135,434 Added 49.8%
12,439,514 $930 Million
Q4 2019

Feb 14, 2020

SELL
$61.62 - $67.78 $93.2 Million - $103 Million
-1,512,563 Reduced 15.41%
8,304,080 $540 Million
Q3 2019

Nov 14, 2019

SELL
$62.51 - $69.0 $1.92 Million - $2.12 Million
-30,716 Reduced 0.31%
9,816,643 $622 Million
Q2 2019

Aug 15, 2019

BUY
$61.87 - $69.38 $563 Million - $631 Million
9,094,586 Added 1208.14%
9,847,359 $665 Million
Q1 2019

May 14, 2019

BUY
$62.53 - $70.05 $11.8 Million - $13.2 Million
188,180 Added 33.33%
752,773 $48.9 Million
Q4 2018

Feb 14, 2019

SELL
$60.54 - $79.0 $3.96 Million - $5.17 Million
-65,430 Reduced 10.39%
564,593 $35.3 Million
Q3 2018

Nov 13, 2018

BUY
$71.28 - $78.92 $296,025 - $327,754
4,153 Added 0.66%
630,023 $48.6 Million
Q2 2018

Aug 14, 2018

SELL
$64.88 - $75.68 $3.87 Million - $4.52 Million
-59,721 Reduced 8.71%
625,870 $44.3 Million
Q1 2018

May 14, 2018

SELL
$72.84 - $88.8 $21.2 Million - $25.8 Million
-290,812 Reduced 29.78%
685,591 $51.7 Million
Q4 2017

Feb 14, 2018

BUY
$71.15 - $83.52 $8.25 Million - $9.69 Million
116,003 Added 13.48%
976,403 $0
Q3 2017

Nov 14, 2017

BUY
$72.11 - $85.47 $62 Million - $73.5 Million
860,400
860,400 $69.7 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $105B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.